MS-275联合平阳霉素对Tca-8113细胞生长和凋亡的影响  

Effect of Combined Application of Histone Deacetylase Inhibitors(HDACIs) MS-275 and Pingyangmycin(PYM) on the Growth and Apoptosis of Oral Squamous Carcinoma Cell

作　　者：周建宇[1] 毛立民[1] 王巍[1] 吕少华[1] 赵晶[1] 

机构地区：[1]哈尔滨医科大学附属第一医院,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2014年第33期6407-6410,共4页Progress in Modern Biomedicine

摘　　要：目的:观察组蛋白去乙酰化酶抑制剂(HDACIs)MS-275联合抗生素类化疗药物平阳霉素(PYM)对口腔鳞状癌细胞Tca-8113的生长及凋亡的影响。方法:以体外培养的口腔鳞状细胞癌Tca-8113细胞为研究对象,应用MTT法检测不同浓度(0、1、2、4、8μmol/L)MS-275、(0、0.05、0.1、0.2、0.4μmol/L)平阳霉素(PYM)单独和联合用药对Tca-8113细胞增殖活性的影响;Annexin-V-FITC/PI双染流式细胞术定量检测细胞的凋亡情况。结果:不同浓度(1、2、4、8μmol/L)MS-275和(0.05、0.1、0.2、0.4μmol/L)PYM均可显著抑制Tca-8113细胞的增殖,并促进其凋亡,且呈浓度依赖性(P<0.05)。4μmol/L MS-275和0.2μmol/L PYM联合应用时,其抑制Tca-8113细胞增殖和促进其凋亡的作用均显著高于单独应用MS-275或PYM(P<0.05)。结论:MS-275能有效增强口腔鳞状细胞癌Tca-8113细胞对平阳霉素(PYM)的敏感性,体外实验中呈现较好的抗肿瘤效应。Objective： To investigate the influence of combined application of histone deacetylase inhibitors MS-275 and antibiotics, chemotherapy drugs Pingyangmycin on the growth and apoptosis of oral squamous carcinoma cell Tca-8113. Methods： Oral squamous cell carcinoma Tca-8113 cells cultured in vitro were used for the study, MTT was performed to examine the proliferative activity of Tca-8113 cells after separated or combined application of（0, 1, 2, 4, 8μmol/L） MS-275and（0, 0.05, 0.1, 0.2, 0.4 μmol/L）PYM; Annexin V-FITC/PI double dye, Flow cytometry was used to detect the effects of MS-275 plus PYM on the apoptosis of Tca-8113 cells. Results： Different concentrations（1, 2, 4, 8 μmol/L） of MS-275 or（0.05, 0.1, 0.2, 0.4 μmol/L） PYM could both inhibit the growth and induce the apoptosis of Tca-8113 cells at a concentration dependent manner（P〈0.05）. Compared with MS-275 or PYM alone, 4μmol/L MS-275 plus 0.2 μmol/L PYM could more significantly inhibit the proliferation of Tca-8113 cells and promote the apoptosis（P〈0.05）. Conclusion： MS-275 could effectively enhance the sensitivity of Tca-8113 cells to PYM, which showed good anti-tumour effect in vitro.

关 键 词：MS-275 平阳霉素 口腔鳞状细胞癌 细胞凋亡 细胞增殖 

分 类 号：Q813[生物学—生物工程] R739.8[医药卫生—肿瘤]